Shionogi & Co., Ltd. (OTCMKTS:SGIOY) Sees Large Increase in Short Interest

Shionogi & Co., Ltd. (OTCMKTS:SGIOY) was the recipient of a large increase in short interest during the month of September. As of September 30th, there was short interest totalling 5,900 shares, an increase of 118.5% from the September 15th total of 2,700 shares. Based on an average daily trading volume, of 113,200 shares, the days-to-cover ratio is currently 0.1 days.

Shionogi & Co., Ltd. Stock Performance

Shares of OTCMKTS:SGIOY traded down $0.01 on Friday, hitting $6.94. The company’s stock had a trading volume of 83,568 shares, compared to its average volume of 84,809. The company has a debt-to-equity ratio of 0.01, a quick ratio of 5.37 and a current ratio of 5.86. The company has a market capitalization of $8.23 billion, a price-to-earnings ratio of 7.15, a price-to-earnings-growth ratio of 6.62 and a beta of 0.22. The stock’s 50-day moving average is $10.46 and its two-hundred day moving average is $10.80. Shionogi & Co., Ltd. has a 12 month low of $6.22 and a 12 month high of $9.11.

Shionogi & Co., Ltd. (OTCMKTS:SGIOY) last announced its earnings results on Monday, July 29th. The company reported $0.17 EPS for the quarter. The business had revenue of $625.99 million during the quarter. Shionogi & Co., Ltd. had a return on equity of 11.95% and a net margin of 35.53%. On average, equities research analysts forecast that Shionogi & Co., Ltd. will post 0.21 EPS for the current year.

Shionogi & Co., Ltd. Company Profile

Shionogi & Co, Ltd. engages in the research, development, manufacture, and distribution of pharmaceuticals, diagnostic reagents, and medical devices in Japan. It offers Fetroja, a multidrug-resistant for gram-negative bacterial infection treatment; Cabenuva and Apretude an anti-HIV and HIV prophylactic drug; Xocova an oral COVID-19 treatment drug; Finibax a carbapenem antibiotic; Xofluza, an influenza antiviral drug; and Tivicay, an anti-HIV drug.